Whether this adaptation involves a selective elimination of cells bearing passenger mutations, or an enrichment for a clonally derived set of tumor cells, it would appear that the exposure to a relatively short period of anti-VEGFR therapy selects for a unique set of tumor cells in each tumor. Here, KDR is linked to neoplasm.